© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Viking Therapeutics Advances 3 Potential Obesity Treatments Based on Promising 2024 Clinical Trial Results
February 06, 2025
A GLP-1/GIP dual agonist in both subcutaneous and oral tablet formulations and a novel dual amylin and calcitonin receptor agonist lead the company's pipeline for antiobesity medications.
Premature Menopause May Increase Risk of Type 2 Diabetes Suggests Study of 1.1 Million Women
February 05, 2025
Premature menopause, authors said, should be included in diabetes management guidelines as a risk factor to support screening and prevention.
New ACP Guidelines on Prevention of Episodic Migraine Cite Lack of Comparative Evidence for Treatments
February 05, 2025
Pharmacologic treatment to prevent episodic migraine should follow a sequential trial approach that considers medication cost, headache triggers, adherence, and lifestyle interventions.
Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial
February 04, 2025
With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.
World Cancer Day 2025: 7 Screening Recommendations from the USPSTF
February 04, 2025
World Cancer Day 2025 urges focus on the unique personal journey underlying every cancer diagnosis; individual recommendations for regular screening is where that can start.
Inhaled Psychedelic GH001 Significantly and Rapidly Reduces Symptoms in Treatment Resistant Depression in Phase 2b Clinical Trial
February 04, 2025
GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.
Where Will the New Nonopioiod Suzetrigine (Journavx) Fit Best Along the Acute Pain Management Continuum? Phase 3 Investigator Shares Thoughts
February 03, 2025
Suzetrigine (Journavx) PI Todd Bertoch, MD, identifies the sweet spot where he thinks the new NaV1.8 inhibitor will be most effective in post-surgical and other moderate-to-severe acute pain.
Global Migraine Burden Rising Fastest Among Men and Adolescents, New Research Finds
February 03, 2025
The global burden of migraine rose by 58% between 1990 and 2021 to more than 1 billion, a pace projected to continue and most rapidly among men and young people.
Vaccine Distrust, Emboldened During the Pandemic, Runs Deep: An Expert Perspective
February 02, 2025
Robert Hopkins, Jr, MD, says of official communications during the COVID-19 pandemic that not enough was explained to the public about policy shifts, leaving people wondering.
Symbravo (AXS-07) for Treatment of Acute Migraine in Adults: Phase 3 Trial Primer
January 31, 2025
The pivotal INTERCEPT and MOMENTUM phase 3 clinical trials served as foundational evidence for the efficacy of the combination therapy across migraine presentations.